Historical award
Xequel Bio, Inc.
This record is historical buying context, not open work.
How current is this award history?
Fiscal year 2025: data through (14 days old).
Fiscal year 2026: data through (14 days old).
Official release availability details
Fiscal year 2025: This is the latest release listed by USAspending. A latest release can still omit recent activity.
Availability checked: .
Fiscal year 2026: This is the latest release listed by USAspending. A latest release can still omit recent activity.
Availability checked: .
- Current award value
- $999,960.15
- Potential award value
- $999,960.15
- Total obligated to date
- $999,960.15
Source date: Nov 9, 2026
Recorded work
ARMY SBIR MEDICAL R&D CONTRACT FOR "PROPOSAL A2-6647 TITLED, "A NOVEL PEPTIDE-BASED TOPICAL THERAPEUTIC TO PROMOTE CORNEAL REGENERATION AND RESTORE CORNEAL BIOMECHANICS FOLLOWING BLAST AND BURN INJURIES" FIRSTSTRING RESEARCH, INC HAS BEEN ACQUIRED BY XEQUEL BIO. INC.
Award activity
- Obligations in covered fiscal years
- −$550,000.00
- Transactions in covered fiscal years
- 1
Award value and obligated funds describe different amounts. Review the official record for the full transaction history.
Record identifier
CONT_AWD_W81XWH17C0065_9700_-NONE-_-NONE-